NIKKEI 225
38,073.98 -128.42 (-0.34%) HANG SENG
18,537.81 +223.91 (+1.22%) CRUDE OIL
79.57 +0.31 (+0.39%) GOLD FUTURES
2,353.10 +12.80 (+0.55%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
49,944.82 +859.73 (+1.75%)
MRNA Oct 2024 135.000 call
| Previous close | 10.75 |
| Open | 10.25 |
| Bid | 11.10 |
| Ask | 11.50 |
| Strike | 135.00 |
| Expiry date | 2024-10-18 |
| Day's range | 10.22 - 10.75 |
| Contract range | N/A |
| Volume | |
| Open interest | 445 |
- Bloomberg
Moderna's Promise of mRNA Undercut by New RSV Vaccine
Moderna's second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Gerry Smith reports on Bloomberg Television.
Simply Wall St.Positive week for Moderna, Inc. (NASDAQ:MRNA) institutional investors who lost 6.8% over the past year
Key Insights Significantly high institutional ownership implies Moderna's stock price is sensitive to their trading...
BloombergModerna’s First Vaccine Was a Big Hit. Its Second Is a Let Down
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t Track‘Seriously Underwater’ Home Mortgages Tick Up Across th
